Rabii Madi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rabii Madi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Martha K. Terris
Medical College of Georgia, Department of Urology, 1447 Harper Street, Augusta, GA, 30912, United States of America
3 shared publications - Rashid K. Sayyid
Institute of Urology, Norris Comprehensive Cancer Center University of Southern California Los Angeles CA USA
2 shared publications Sravan Kavuri
Department of Pathology, Medical College of Georgia, Augusta University Health, Augusta, Georgia, USA
2 shared publications- Zachary Klaassen
Department of Urology, Medical College of Georgia at Augusta University (Wellstar MCG Health), Augusta, GA
2 shared publications Anthony Hiffa
Division of Urology, Department of surgery, Augusta University Health, Augusta, Georgia, USA
1 shared publicationAsad Ullah
Department of Pathology, Medical College of Georgia, Augusta University Health, Augusta, Georgia, USA
1 shared publication
Latest Publications
- Open Access
- 18 October 2021
- Published by Elsevier in Urology Case Reports
- Vol. 40, 101884
Collision metastasis: Renal cell carcinoma and prostatic adenocarcinoma to a retroperitoneal lymph node
- 18 October 2021
- Published by Elsevier in Urology Case Reports
- Vol. 40, 101884
Open AccessCollision metastasis: Renal cell carcinoma and prostatic adenocarcinoma to a retroperitoneal lymph node
- 1 December 2020
- Published by SAGE Publications in Journal of Endourology Case Reports
- Vol. 6 (4) , 322-324
Renal Cell Carcinoma Presenting as an Isolated Eyelid Metastasis
Background: Renal cell carcinoma (RCC) has a propensity to metastasize with the most common sites of metastasis being the lungs and bones. Cutaneous metastasis of RCC to the eyelid is exceedingly rare, with only six cases reported in the past decade. We are reporting a case of metastatic renal cell carcinoma (mRCC) that presented with a painless eyelid mass. Case Presentation: We describe a case of a 66-year-old man with a history of chronic kidney disease stage III presenting with a rapidly growing left lower eyelid lesion thought to be a capillary hemangioma. Biopsy revealed polygonal clear cells with small central nuclei with thin-walled vasculature and strong immunostaining with PAX8 consistent with mRCC, clear cell type. Subsequent abdominal CT scan revealed a 5.1 × 4.7 × 4.3 cm heterogeneously enhancing mass with central necrosis in the upper pole of the left kidney. The patient was treated with excision of the eyelid lesion followed by robotic partial nephrectomy of the primary tumor. Follow-up CT scan at 3 and 6 months showed no evidence of recurrence. Conclusion: Isolated eyelid metastasis is an extremely rare form of presentation of mRCC. Interestingly, that patient did not have any other site of metastasis. Cytoreductive partial nephrectomy has been previously reported to be oncologically safe in selected patients.
- 1 December 2020
- Published by SAGE Publications in Journal of Endourology Case Reports
- Vol. 6 (4) , 322-324
Renal Cell Carcinoma Presenting as an Isolated Eyelid Metastasis
Background: Renal cell carcinoma (RCC) has a propensity to metastasize with the most common sites of metastasis being the lungs and bones. Cutaneous metastasis of RCC to the eyelid is exceedingly rare, with only six cases reported in the past decade. We are reporting a case of metastatic renal cell carcinoma (mRCC) that presented with a painless eyelid mass. Case Presentation: We describe a case of a 66-year-old man with a history of chronic kidney disease stage III presenting with a rapidly growing left lower eyelid lesion thought to be a capillary hemangioma. Biopsy revealed polygonal clear cells with small central nuclei with thin-walled vasculature and strong immunostaining with PAX8 consistent with mRCC, clear cell type. Subsequent abdominal CT scan revealed a 5.1 × 4.7 × 4.3 cm heterogeneously enhancing mass with central necrosis in the upper pole of the left kidney. The patient was treated with excision of the eyelid lesion followed by robotic partial nephrectomy of the primary tumor. Follow-up CT scan at 3 and 6 months showed no evidence of recurrence. Conclusion: Isolated eyelid metastasis is an extremely rare form of presentation of mRCC. Interestingly, that patient did not have any other site of metastasis. Cytoreductive partial nephrectomy has been previously reported to be oncologically safe in selected patients.
- 29 May 2020
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 15 (2) , 221-228
Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: racial considerations for 250 consecutive cases
Our objective is to report the functional and oncologic outcomes of a cohort of 250 consecutive prostate cancer patients undergoing a Retzius-sparing approach and to assess for racial differences in continence outcomes. This was a prospective, single-center, case series of 250 consecutive prostate cancer patients who underwent a Retzius-sparing robotic-assisted laparoscopic radical prostatectomy by a single surgeon between May 2015 and April 2019. Our primary objective was to report post-operative continence outcomes of patients undergoing this technique. Continence was defined as using zero or one precautionary pad per day. Median follow-up was 24.0 months [interquartile range (IQR) 18.0–30.0 months]. Median age and body mass index were 62.0 years (IQR 57.0–67.0) and 29.0 kg/m2 (IQR 26.0–33.0), respectively. Median PSA was 8.22 ng/ml (IQR 5.74–13.31). 84.8% of patients were intermediate risk or high risk pre-operatively, as per AUA/ASTRO/SUO guidelines. 96.0% had Gleason Score 7 or worse disease on final pathologic analysis. Positive margin incidence was 18.1% and 44.4% in patients with pT2 and pT3 disease, respectively, of which 75.4% were unifocal. Immediate continence (i.e., continence achieved within 1 month post-operatively) was achieved in 45.2% of patients. Three-month and 1-year continence rates were 70.0% and 92.0%, respectively. Caucasian patients experienced earlier return of continence (77% versus 65% at 3 months) compared to African American patients. IPSS scores gradually improved from 8.0 pre-operatively to 4.0 1-year later. Median PSA level was 0.01 ng/ml (IQR 0.01–9.01) post-operatively. Retzius-sparing robotic-assisted laparoscopic radical prostatectomy is an oncologically safe surgical technique with excellent short- and long-term continence outcomes. Caucasian patients may have earlier return of continence compared to African Americans.
- 29 May 2020
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 15 (2) , 221-228
Retzius-sparing robotic-assisted laparoscopic radical prostatectomy: racial considerations for 250 consecutive cases
Our objective is to report the functional and oncologic outcomes of a cohort of 250 consecutive prostate cancer patients undergoing a Retzius-sparing approach and to assess for racial differences in continence outcomes. This was a prospective, single-center, case series of 250 consecutive prostate cancer patients who underwent a Retzius-sparing robotic-assisted laparoscopic radical prostatectomy by a single surgeon between May 2015 and April 2019. Our primary objective was to report post-operative continence outcomes of patients undergoing this technique. Continence was defined as using zero or one precautionary pad per day. Median follow-up was 24.0 months [interquartile range (IQR) 18.0–30.0 months]. Median age and body mass index were 62.0 years (IQR 57.0–67.0) and 29.0 kg/m2 (IQR 26.0–33.0), respectively. Median PSA was 8.22 ng/ml (IQR 5.74–13.31). 84.8% of patients were intermediate risk or high risk pre-operatively, as per AUA/ASTRO/SUO guidelines. 96.0% had Gleason Score 7 or worse disease on final pathologic analysis. Positive margin incidence was 18.1% and 44.4% in patients with pT2 and pT3 disease, respectively, of which 75.4% were unifocal. Immediate continence (i.e., continence achieved within 1 month post-operatively) was achieved in 45.2% of patients. Three-month and 1-year continence rates were 70.0% and 92.0%, respectively. Caucasian patients experienced earlier return of continence (77% versus 65% at 3 months) compared to African American patients. IPSS scores gradually improved from 8.0 pre-operatively to 4.0 1-year later. Median PSA level was 0.01 ng/ml (IQR 0.01–9.01) post-operatively. Retzius-sparing robotic-assisted laparoscopic radical prostatectomy is an oncologically safe surgical technique with excellent short- and long-term continence outcomes. Caucasian patients may have earlier return of continence compared to African Americans.
- Open Access
- 1 January 2018
- Published by Medknow in Urology Annals
- Vol. 10 (3) , 342-344
Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder
The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%–28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.
- 1 January 2018
- Published by Medknow in Urology Annals
- Vol. 10 (3) , 342-344
Open AccessCollision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder
The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%–28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.
- 1 December 2017
- Published by SAGE Publications in Journal of Endourology
- Vol. 31 (12) , 1244-1250
Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy: A Safe Surgical Technique with Superior Continence Outcomes
Purpose: To report early operative outcomes and asses continence in 100 consecutive patients who underwent Retzius-sparing robotic-assisted laparoscopic radical prostatectomy Materials and Methods: This was a prospective, single-center, consecutive case series of 100 and 100 patients undergoing a Retzius-sparing and a conventional robotic-assisted laparoscopic radical prostatectomy, respectively, by a single surgeon between March 2015 and April 2017. Results: Baseline patient characteristics were similar between the two groups. The Retzius-sparing approach required significantly less console time (120.0 vs. 144.0 mins, p<0.001). There were no differences in intra- or post-operative complication rates and hospital length of stay was similar in the two groups. Incidence of positive surgical margins was non-significantly different between the two groups, with 17% and 13% of pT2 patients and 49% and 48% of pT3 patients in the Retzius-sparing and conventional groups, respectively. Patients in the Retzius-sparing group had significantly superior rates of achieving post-operative urinary continence (log-rank test: p<0.001), with 20% of patients continent within the first month, compared to 8% of patients in the conventional group. Mean number of pads per day needed at three, six, nine, and 12 months post-operatively was also significantly lower in the Retzius-sparing group. Conclusions: Retzius-sparing robotic-assisted laparoscopic radical prostatectomy requires shorter console time, is oncologically safe, and leads to significantly superior continence outcomes compared to conventional robotic-assisted laparoscopic radical prostatectomy.
- 1 December 2017
- Published by SAGE Publications in Journal of Endourology
- Vol. 31 (12) , 1244-1250
Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy: A Safe Surgical Technique with Superior Continence Outcomes
Purpose: To report early operative outcomes and asses continence in 100 consecutive patients who underwent Retzius-sparing robotic-assisted laparoscopic radical prostatectomy Materials and Methods: This was a prospective, single-center, consecutive case series of 100 and 100 patients undergoing a Retzius-sparing and a conventional robotic-assisted laparoscopic radical prostatectomy, respectively, by a single surgeon between March 2015 and April 2017. Results: Baseline patient characteristics were similar between the two groups. The Retzius-sparing approach required significantly less console time (120.0 vs. 144.0 mins, p<0.001). There were no differences in intra- or post-operative complication rates and hospital length of stay was similar in the two groups. Incidence of positive surgical margins was non-significantly different between the two groups, with 17% and 13% of pT2 patients and 49% and 48% of pT3 patients in the Retzius-sparing and conventional groups, respectively. Patients in the Retzius-sparing group had significantly superior rates of achieving post-operative urinary continence (log-rank test: p<0.001), with 20% of patients continent within the first month, compared to 8% of patients in the conventional group. Mean number of pads per day needed at three, six, nine, and 12 months post-operatively was also significantly lower in the Retzius-sparing group. Conclusions: Retzius-sparing robotic-assisted laparoscopic radical prostatectomy requires shorter console time, is oncologically safe, and leads to significantly superior continence outcomes compared to conventional robotic-assisted laparoscopic radical prostatectomy.